
Pulled from Benzinga Pro data, Humacyte (NASDAQ:HUMA) posted Q4 earnings of $42.59 million, an increase from Q3 of 234.92%. Sales dropped to $177.00 thousand, a 26.56% decrease between quarters. Humacyte collected $241.00 thousand in revenue during Q3, but reported earnings showed a $31.56 million loss.